Fig. 6

Targeting ATG7 enhances the efficacy of anti–PD-1 therapy. (A) Schematic diagram of the drug intervention protocol utilizing the ATG7 inhibition and/or anti-PD-1 antibody to treat C57BL/6 mice. Image of isolated tumors and tumor growth curves (B, D) and tumor weight (C, E) of MC38 xenografts treated with control (shNC, vehicle) or ATG7 inhibition (shATG7, ATG7-IN-1) combined with anti-PD-1